Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Sciences Division is delighted to welcome Dr Anjan Thakurta to Oxford, having now taken up his position of Visiting Professor of Cancer, Biology and Translational Science within the Radcliffe Department of Medicine.

None

Dr Thakurta will provide strategic support and advice to the Medical Sciences Division and foster new collaborations between the University of Oxford and Celgene. He will also facilitate greater access to and opportunities with senior Celgene scientists for University of Oxford researchers, enabling them to gain a deeper understanding of the scope and potential of Celgene’s portfolio of work and an industry perspective on research questions. Whilst in Oxford, Dr Thakurta will be based in the MRC Weatherall Institute of Molecular Medicine (MRC WIMM).

Dr Thakurta brings extensive knowledge of Celgene’s early therapeutic pipeline and translational biology programmes, especially in haematology / oncology, and over 20 years’ experience in translational and clinical drug development. Most recently, leading the myeloma disease team, one of Celgene’s major disease areas. Prior to this, he led translational and diagnostic work across all haematological areas in Celgene.

Dr Thakurta brings with him a wealth of experience in mentoring scientists in the early stages of their careers, and has previously supervised Oxford-Celgene fellows.  His advice on Oxford-Celgene Fellowship Programme applications will not only support the development of cutting-edge science, but also the training of the next generation of scientists and clinical academics.

 

As Visiting Professor, I will visit Oxford regularly, interact with current and potential future fellows and look forward to establishing some new and exciting collaborations and translational initiatives at the university over the next three years. - Dr Anjan Thakurta, Celgene

 

I am really pleased Dr Thakurta has been awarded the position of Visiting Professorship and has taken this up position. Dr Thakurta has a wealth of experience in drug development especially in haematological disease and has already mentored two young aspiring clinical academics, who have successfully started their independent careers in Oxford. He has also made important links with a number of Oxford groups and I am sure these new relationships will be enormously productive, helping to transform patient care as well as providing wonderful academic opportunities for Oxford University, Oxford University Hospitals NHS Foundation Trust and Celgene - Professor Paresh Vyas, Professor of Haematology, MRC Molecular Haematology Unit, MRC WIMM, University of Oxford

 

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Medical Sciences Division receives REF 2021 results

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021. REF is the UK-wide assessment of research in universities, and provides an expert evaluation of the quality of the research outputs, impact and environment at subject level in each university.